Experience firsthand insights from company CEOs, secure direct access to high-quality investments and join a sophisticated network of successful investors.
Friday, 7th June 1pm (AEST)
Live Investor Briefing
Please join Plutonic Non-Executive Chairman Hedley Widdup for an investor briefing. In this session, Hedley will discuss why he thinks their flagship project could define a new mining district rivalling the biggest copper-gold projects in the world.
Speaker
Joseph Webb Executive Director
19th April 2025
19th March 2025
19th July 2025
29th May 2024
Joyned is an E-commerce technology company that is revolutionising how online purchases are made. Partnered with €31 B travel giant Amadeus, the business is rolling out its solution, targeting the $2.3 trillion-dollar global tourism industry.
DR Gerard Dyson
Managing Director – Spectur Limited (ASX: SP3)
John Forwood, CIO of Lowell Resources Fund, discusses his ‘blue-sky’ thesis for Plutonic and compares it to previous portfolio winners.
Hedley Widdup, CEO of leading resources fund manager Lion Selection Group (ASX:LSX), discusses why he believes that Plutonic represents a “once in a cycle” opportunity, elaborating on their progress and pathway to IPO.
Plutonic founder Dr Kris Butera discusses his flagship Champion project, expanding on why he believes there is potential for a resource deposit that is “unlike anything he has ever seen.”
25th March 2024
In this session Prescient CEO and Managing Director Steven Yatomi-Clarke provide a company update on strategy and upcoming milestones.
15th February 2024
In this session Wellnex Life MD Zack Bozinovski and Non-Executive Chairman Mario Tascone discussed what attracted Mario to Wellnex and where he sees the future of the business;
19th February 2025
19th May 2025
16th May 2024
In this session Felix Gold Executive Director Joseph Webb discussed their plans to develop a potential multi million ounce high grade gold resource.
DR Gerard Dyson Managing Director – Spectur Limited (ASX: SP3)
18th April 2024
In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.
9th April 2024
In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed why the data from their PTX-100 Phase 1b trial is so promising.
14th March 2024
Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.
22nd February 2024
In this session Far East Gold’s CEO and Director Shane Menere discussed, why the Board (including Nickel Industries MD Justin Werner) is optimistic about the findings so far……
14th February 2024
In this session VP Minerals (VPM) Non-Executive Director Graham Howard discussed VPM’s continued resource inventory targeting high grade critical mineral deposits.
In this session Propell CEO Michael Davidson discussed Propell’s recent progress on the platform, cost base, and establishing a broker network…
19th November 2025
7th November 2023
Propell (ASX: PHL) CEO Michael Davidson discusses how the company is successfully disrupting the banks with its innovative lending model, its exponential growth in its user base and revenues in the past year, and plans to take a significant portion of Australia’s $423 billion SME loan book.
9th November 2022
Aerometrex (ASX: AMX) is a professional aerial mapping business, specialising in aerial imagery, photogrammetry, LiDAR, 3D modelling and aerial imagery subscription services.
This week we were joined by the CEOs of exciting ASX listed businesses: Credit Clear Limited (ASX: CCR) and Race Oncology Limited (ASX: RAC)
8th November 2022
Wellnex Life Limited (ASX: WNX) an Australian brand innovation and distribution company operating within the $10.7 billion Australian health and wellness market
3rd November 2022
Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses how Prescient is advancing its deep pipeline, including moving OmniCAR towards clinical studies and progressing PTX-100 and PTX-200 further through the clinic. What the recent Q-Gen contract means for producing first OmniCAR T-cells for upcoming clinical trials, based on the encouraging progress of the AML program.
21st October 2022
Spectur (ASX: SP3) MD Gerard Dyson discusses how the company’s wide technological moat leaves the company with no direct competition, its weighted sales pipeline which has grown 94% year-on-year as at June 2022, and how Spectur are ready to scale and move into its next growth phase.
14th October 2022
Wellnex Life (ASX: WNX) CEO George Karafotias and CSO Zack Bozinovski provide an overview of the over-the-counter medicinal cannabis opportunity in a special investor briefing.
4th October 2022
29th September 2022
28th September 2022
Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company focused on developing next-generation personalised cancer therapies within the total global US$280 billion (2021) oncology industry.
This week we were joined by the CEOs of exciting ASX listed businesses: Prescient Therapeutics Limited (ASX: PTX) and Aerometrex (ASX: AMX).
15th September 2022
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.